Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer
This is a randomized, open-label, multi-center, phase II trial to evaluate the efficacy and safety of SHR-1210 plus apatinib mesylate versus Pemetrexed and Carboplatin in Subjects with KRAS mutant stage IV non-squamous Non-small Cell Lung Cancer
NSCLC Stage IV|KRAS Gene Mutation|PD-1 Antibody|Chemotherapy Effect
DRUG: SHR-1210|DRUG: Apatinib|DRUG: Pemetrexed|DRUG: Carboplatin
Duration of Progression-Free Survival (PFS) as Assessed by the Independent Review Committee Using RECIST v1.1, PFS, defined as the time from randomization to the first occurrence of disease progression as determined by the Independent Review Committee Using RECIST v1.1 or death from any cause, whichever occurs first. Patients who have not experienced disease progression or death at the time of analysis will be censored at the time of last tumor assessment., up to approximately 40 months
Duration of Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1, Time Frame: Baseline until PD or death, whichever occurs first, up to approximately 40 months|Duration of Overall Survival (OS), Baseline until death from any cause, up to approximately 40 months|Objective Response Rate (ORR), The percentage of patients with CR and PR assessed by investigators according to Recist v 1.1., up to approximately 40 months|disease control rate (DCR), The proportion of patients who have achieved complete response， partial response and Stable disease assessed by investigators according to Recist v 1.1., up to approximately 40 months|Duration of response （DoR）, Duration of response （DoR）, up to approximately 40 months|Adverse events (AEs), All adverse event/Serious adverse event that occurred during the study period according to CTCAE v 5.0, up to approximately 40 months
This is a randomized, open-label, multi-center, phase II trial to evaluate the efficacy and safety of SHR-1210 plus apatinib mesylate versus Pemetrexed and Carboplatin in Subjects with KRAS mutant stage IV non-squamous Non-small Cell Lung Cancer